ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,499,657 | -20.2% | 322,571 | +3.3% | 0.00% | -33.3% |
| Q2 2023 | $14,409,305 | +17.9% | 312,363 | +2.5% | 0.00% | +50.0% |
| Q1 2023 | $12,218,871 | -11.4% | 304,710 | +2.3% | 0.00% | -33.3% |
| Q4 2022 | $13,797,676 | -1.1% | 297,813 | -11.6% | 0.00% | 0.0% |
| Q3 2022 | $13,955,000 | -30.3% | 336,996 | +0.4% | 0.00% | -25.0% |
| Q2 2022 | $20,015,000 | -18.4% | 335,493 | -0.7% | 0.00% | 0.0% |
| Q1 2022 | $24,523,000 | -14.1% | 337,696 | -0.5% | 0.00% | -20.0% |
| Q4 2021 | $28,553,000 | -7.7% | 339,549 | -1.0% | 0.01% | 0.0% |
| Q3 2021 | $30,919,000 | -5.8% | 342,813 | -0.4% | 0.01% | -16.7% |
| Q2 2021 | $32,808,000 | -60.6% | 344,081 | -53.0% | 0.01% | -60.0% |
| Q1 2021 | $83,296,000 | -22.4% | 731,568 | -5.7% | 0.02% | -28.6% |
| Q4 2020 | $107,393,000 | +76.0% | 775,791 | +4.5% | 0.02% | +61.5% |
| Q3 2020 | $61,006,000 | +0.2% | 742,255 | -4.6% | 0.01% | -7.1% |
| Q2 2020 | $60,890,000 | +90.0% | 778,449 | +8.0% | 0.01% | +55.6% |
| Q1 2020 | $32,039,000 | +5.6% | 721,103 | +1.5% | 0.01% | +28.6% |
| Q4 2019 | $30,343,000 | -2.1% | 710,453 | -1.9% | 0.01% | 0.0% |
| Q3 2019 | $30,981,000 | -29.4% | 724,177 | +4.8% | 0.01% | -30.0% |
| Q2 2019 | $43,886,000 | -3.9% | 691,110 | +5.0% | 0.01% | -9.1% |
| Q1 2019 | $45,660,000 | +80.9% | 658,298 | +13.4% | 0.01% | +57.1% |
| Q4 2018 | $25,243,000 | -41.9% | 580,580 | +2.0% | 0.01% | -36.4% |
| Q3 2018 | $43,463,000 | +2.0% | 569,322 | +2.7% | 0.01% | 0.0% |
| Q2 2018 | $42,594,000 | +60.9% | 554,092 | +6.7% | 0.01% | +57.1% |
| Q1 2018 | $26,471,000 | +23.9% | 519,150 | +12.7% | 0.01% | +40.0% |
| Q4 2017 | $21,364,000 | -15.0% | 460,643 | -2.4% | 0.01% | -28.6% |
| Q3 2017 | $25,140,000 | -15.2% | 472,019 | -1.1% | 0.01% | -12.5% |
| Q2 2017 | $29,651,000 | -4.5% | 477,401 | +4.2% | 0.01% | -11.1% |
| Q1 2017 | $31,060,000 | +3.0% | 458,263 | +6.9% | 0.01% | 0.0% |
| Q4 2016 | $30,144,000 | +0.0% | 428,726 | +0.9% | 0.01% | 0.0% |
| Q3 2016 | $30,134,000 | +44.7% | 424,774 | -0.2% | 0.01% | +28.6% |
| Q2 2016 | $20,821,000 | -27.1% | 425,694 | -3.6% | 0.01% | -22.2% |
| Q1 2016 | $28,570,000 | -40.6% | 441,748 | +3.0% | 0.01% | -43.8% |
| Q4 2015 | $48,122,000 | +18.8% | 428,973 | +2.0% | 0.02% | +14.3% |
| Q3 2015 | $40,503,000 | +191.5% | 420,532 | +209.9% | 0.01% | +250.0% |
| Q2 2015 | $13,895,000 | +100.4% | 135,710 | +21.5% | 0.00% | +100.0% |
| Q1 2015 | $6,935,000 | +51.8% | 111,688 | +7.3% | 0.00% | +100.0% |
| Q4 2014 | $4,568,000 | -22.8% | 104,092 | -0.4% | 0.00% | -50.0% |
| Q3 2014 | $5,917,000 | +51.8% | 104,557 | +20.4% | 0.00% | +100.0% |
| Q2 2014 | $3,897,000 | +175.6% | 86,811 | +200.0% | 0.00% | – |
| Q1 2014 | $1,414,000 | – | 28,939 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |